Peptide & experimental

KLOW (KPV + GHK-Cu + BPC-157 + TB-500)

Peptide blend – GLOW plus KPV for skin, gut & inflammation · KLOW blend, GLOW + KPV, healing stack

KLOW is the big brother of the GLOW stack: the same three healing peptides GHK-Cu, BPC-157 and TB-500, supplemented with KPV, a tiny anti-inflammatory fragment of the hormone alpha-MSH. This shifts the target from the skin alone to skin, gut and inflammation. The idea is biologically elegant; the combination has never been tested.

In short

KLOW combines 4 peptides, each with its own role: TB-500 is supposed to mobilize repair cells, BPC-157 to supply blood vessels and the gut lining, GHK-Cu to direct collagen formation and KPV to curb inflammation. Each ingredient on its own has interesting cell and animal data; KPV, for example, reduced gut inflammation in a mouse model, even when given by mouth. There is not a single study on the four-way combination, and none of the ingredients has been properly studied in humans in injectable form. KLOW is a research blend without approval.

What it is

The name says it all: GLOW plus K. The K stands for KPV, a tripeptide of 3 amino acids, lysine, proline and valine. It is the tail end of alpha-MSH, a hormone produced by the body that, among other things, dampens inflammation. The melanotans mimic the tanning part of the same molecule; KPV, by contrast, mimics only the anti-inflammatory end, without tanning.

The other three ingredients are familiar from the GLOW stack. GHK-Cu is a copper-containing peptide that occurs in blood and saliva and is associated with skin regeneration and collagen formation. BPC-157 is derived from a protective protein in gastric juice and is the classic of the regeneration scene. TB-500 is a fragment of thymosin beta-4 that is said to promote the mobility of repair cells. KLOW is usually sold as a pre-mixed vial.

The logic of the four roles

The scene describes KLOW as a construction site with four trades. The roles are derived from cell and animal experiments, not demonstrated in humans. TB-500 brings the construction workers, that is, repair cells, to the site. BPC-157 builds the supply routes, new small blood vessels, and because of its origin in the stomach is considered a specialist for the gut lining. GHK-Cu supplies the blueprint for collagen and elastin. KPV keeps the site calm, because persistent inflammation slows any healing.

It is precisely this fourth role that the GLOW stack lacks. The scene’s rule of thumb is therefore: those mainly focused on skin and aesthetics stick with GLOW. Those who additionally have gut issues, irritation or skin prone to redness and eczema reach for KLOW. Some people with sensitive skin report that pure build-up stacks tend to irritate them and that the calming KPV makes the difference.

How KPV is supposed to work

Everything in this section comes from cell cultures and animal experiments; none of these steps has been shown in humans. In cell experiments, KPV enters the cell and throttles NF-κB there, the master switch for inflammatory genes. The route in is well described in the laboratory: a transporter called PepT1, which normally takes up small peptides from food, carries KPV into gut and immune cells. In an inflamed colon, this transporter is even produced in greater amounts. This explains why KPV also worked when given by mouth in animals, because as a short tripeptide it survives the passage through the stomach.

In human skin cells, a 2004 paper found that KPV does not signal via the classic messenger cAMP, but does trigger rapid calcium signals. The mechanism is therefore real, but different from that of whole alpha-MSH and not fully understood in humans. A 2023 review of the melanocortin system in inflammatory bowel diseases notes that experience with this approach comes mainly from mouse models of colitis, and sees in it a possible route to new medicines.

What users report

A typical timeline comes from user reports: calming of the gut often after 1 to 3 weeks, because KPV is said to act fastest, improvements in tissue and joints from week 3 to 6, skin changes similar to GLOW from week 3. For purely gut-related use, some take KPV alone by mouth.

Experienced users advise introducing components one at a time rather than starting straight away with the pre-mixed blend, so that a side effect can be attributed to a specific ingredient. The best reports come from people who combine the stack with the basics: identifying dietary triggers, fermented foods, sufficient protein, stress management. These are reports without a control group, not evidence of efficacy.

What is well supported

The individual components are supported, and mostly in the laboratory and in animals. For KPV, a 2008 paper in Gastroenterology showed that the tripeptide inhibits the inflammatory signals NF-κB and MAP kinase in human gut and immune cells and lowers the release of inflammatory messengers. Given in drinking water, it alleviated gut inflammation in mice in 2 different colitis models. For BPC-157, a 2025 systematic review summarized 36 studies, 35 of them preclinical, with better healing of muscle, tendon, ligament and bone in animals. For GHK-Cu, a review describes wound healing in animals and effects of cosmetic products on elasticity and wrinkles, written, however, by the discoverer of the peptide. For thymosin beta-4, the model for TB-500, there are human data mainly from eye and wound healing.

What the studies show

KPV in gut inflammation (Dalmasso, 2008)

The researchers examined human intestinal epithelial cells, human T cells and two mouse models of colitis. KPV had an anti-inflammatory effect even at nanomolar concentrations and was taken up via the transporter PepT1. Given orally via drinking water, the incidence of colitis and the amount of inflammatory messengers fell in the mice. No study in humans has followed so far.

KPV in human skin cells (Elliott, 2004)

In cultures of human keratinocytes, KPV did not trigger a rise in cAMP, the messenger through which alpha-MSH classically acts. Rapid calcium signals were observed, however. The paper shows a separate signaling pathway, but provides no clinical endpoint.

BPC-157 in the systematic review (Vasireddi, 2025)

Of 36 included studies, 35 were preclinical and 1 clinical. In animals, muscle, tendon, ligament and bone healed better. The authors found no clinical safety data.

Where the data stop

There is no published study on the combination of the 4 peptides. Nobody has tested whether the ingredients are compatible in a mixture, whether they remain stable and whether their effects add up. The concept of the four roles is coherently thought out, but it is an addition of individual findings.

The individual components also stand on thin ground in humans. There is no clinical study on KPV. For TB-500, a 2026 review found, among 80 studies on thymosin beta-4 and TB-500, only 1 study that examined TB-500 directly. The human data on thymosin beta-4 mainly concern the eye and skin, hardly tendons, muscles or joints. Another review of six peptides popular in the scene found that 67 percent of publications come from animal models. The reported timelines cannot be separated from natural healing, dietary changes and expectation.

Status, approval and legal

None of the four substances is approved as a medicine in Germany or the EU. KLOW is sold as a research blend on the gray market; the purity and actual content of the mixture are unverified. BPC-157 is banned in professional sports, which makes the blend off-limits for competitive athletes. The same applies to KPV alone as a capsule: there is no approved product, and what circulates in the scene has not been pharmaceutically tested. On July 23–24, 2026, an FDA expert panel discussed whether KPV, TB-500 and BPC-157 should be permitted for compounded medicines in the US. The FDA’s experts advised against it in each case; the panel nonetheless voted in favor by majority in each case (votes 8:6 each, with 1 abstention). An FDA decision is pending; a formal procedure is unlikely to begin before 2027. GHK-Cu was not part of this vote. We do not give dosages for unapproved substances.

Safety

Long-term safety data in humans are missing for all four ingredients in injectable form. Most commonly reported are redness and, with GHK-Cu, a noticeable burning at the injection site caused by the copper; less often headache or fatigue at the start, and with GHK-Cu occasionally dizziness or a drop in blood pressure. KPV is considered well tolerated in the animal models. Because several ingredients promote new blood vessel formation and cell migration, people with active cancer should avoid the stack. Persistent gut complaints should first be checked by a doctor; the blend does not replace a diagnosis.

BK-Score Not studied in humans

Human evidence		0
Mechanism		3
Safety data		0
Hype gap		0
Track record of use		3

The same gap as with the GLOW stack, only with a fourth component: no study on the combination was found. KPV has no clinical study in humans; the data come from human cell cultures and mouse models – in the central paper (Gastroenterology 2008) it inhibited NF-κB in gut and immune cells and, given orally, alleviated colitis in 2 mouse models; in human keratinocytes (J Invest Dermatol 2004) there was no cAMP signal, but a calcium signal. BPC-157 has been studied extensively in preclinical work (36 studies, 35 preclinical), TB-500 directly hardly at all. Four substances, each with thin human data, are added together into a protocol whose overall effect and stability have never been tested. Widespread as a pre-mixed vial in the scene, without a regulatory framework.

The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)

Frequently asked questions about KLOW (KPV + GHK-Cu + BPC-157 + TB-500)

What is the difference between GLOW and KLOW?

KLOW contains the same three peptides as GLOW, that is GHK-Cu, BPC-157 and TB-500, plus KPV. KPV is supposed to dampen inflammation and shifts the target from the skin to skin, gut and inflammation.

What is KPV?

A tripeptide made of lysine, proline and valine, the tail end of the hormone alpha-MSH. In the laboratory and in a mouse model it inhibits inflammatory signals in the gut. There are no studies in humans.

Are there studies on the KLOW stack?

No, no study on the four-way combination has been published. All statements are based on individual data on the ingredients, mostly from cell culture and animal experiments.

Does KLOW help with irritable bowel or leaky gut?

That has not been studied. KPV reduced artificially induced gut inflammation in mice; this cannot be transferred directly to people with gut complaints. Persistent complaints should be checked by a doctor.

What side effects does KLOW have?

Mainly redness and burning at the injection site are reported, less often headache, fatigue or dizziness. There are no systematic safety data. People with active cancer should avoid the stack.

Is KLOW legal?

None of the substances is approved as a medicine; the blend is sold as a research product. In competitive sports it is banned because of BPC-157.

The podcast episode (in German)

Episode 53